Pharmacists in Germany could be permitted to switch biologics with biosimilars if a new bill makes it through the legislative process. Though recent revisions to the bill could delay this measure by three years, once in force, it would likely have a substantial impact on the pharmaceutical industry. Manufacturers of originator biologics could be exposed to lower sales and increased pricing pressure, according to Eda Zhuleku, a life science specialist at the law firm Allen & Overy.
On Jan. 30, the German cabinet approved a revised text of the bill (GSAV, Act for Greater Security in the...








